Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma

This activity will explore strategies for successful stem cell mobilization in multiple myeloma, focusing on optimizing peripheral blood stem cell collection for autologous hematopoietic stem cell transplantation (ASCT). Hamza Hashmi, MD, Assistant Attending Physician in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center and Assistant Professor of Clinical Medicine at Weill Cornell Medical College  will share insights on improving outcomes through interdisciplinary approaches and addressing mobilization challenges

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to

• Evaluate current and emerging data on stem cell mobilization regimens in patients with MM
• Identify patients eligible for ASCT and at high risk of mobilization failure
• Apply interdisciplinary strategies to mitigate poor mobilization and optimize ASCT outcomes

STATEMENT OF NEED

Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Collecting peripheral blood stem cells (PBSCs) is an essential component of ASCT, and the collection of sufficient autologous PBSCs relies on the successful mobilization of hematopoietic stem cells from the bone marrow niche into circulation. Stem cell mobilization strategies differ in terms of stem cell yields, safety considerations, and resource utilization, and mobilization failure remains a concern in spite of the incorporation of novel agents into conventional methods. Therefore, it is crucial that clinicians apply interdisciplinary strategies to mitigate poor mobilization and optimize ASCT outcomes (Wei & Wei, 2023). In this activity, Dr. Hamza Hashmi, Assistant Attending in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center and Assistant Professor of Clinical Medicine at Weill Cornell Medical College, will share insights into cracking the code to successful stem cell mobilization in multiple myeloma. 

TARGET AUDIENCE

Hematologists, medical oncologists, advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with multiple myeloma.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Hamza Hashmi, MD, discloses that he has served on an advisory board or panel for Janssen and that he has served on a speaker's bureau for Amgen, Janssen, and Karyopharm. 

i3 Health has mitigated all relevant financial relationships.